Most independent pharmacy purchases of up to $5 million are financed with an SBA 7(a) loan: up to 10 years for goodwill and inventory, a buyer equity injection of at least 10% of total project costs for a complete change of ownership, and a personal guarantee from every owner of 20% or more. Larger and multi-store deals use conventional senior debt, often beside a line secured by inventory and receivables. Either way, lenders underwrite prescription volume and margin by payer, whether the permits, DEA registration and payer contracts will be in the buyer's name on day one, and who will be the pharmacist-in-charge.
- Usual structure
- SBA 7(a) up to $5 million; conventional senior debt plus an inventory and receivables line for larger or multi-store deals
- Equity (SBA, complete change of ownership)
- At least 10% of total project costs; a seller note on full standby can supply up to half
- What lenders probe hardest
- Gross profit per prescription by payer, script trends, audit clawbacks, the pharmacist-in-charge
- What must be in place at closing
- Pharmacy permit, DEA registration and payer network access in the buyer's name
- Documents beyond the standard list
- Script counts and margin by payer, audit history, permit and registration list, inventory count
Where a pharmacy's earnings actually come from
A pharmacy looks like a retailer and is underwritten like a contractor to health plans. Most of its revenue is prescriptions paid by third parties: commercial plans, Medicare Part D plans and Medicaid, almost all of them adjudicated through pharmacy benefit managers. The pharmacy does not set its price. Its gross profit on a prescription is whatever the payer's contract reimburses, plus the dispensing fee, minus what the drug cost from the wholesaler, minus any fees or adjustments the payer takes back later. That last item is why lenders do not stop at the top line.
The front of the store, over-the-counter products, gifts and convenience items, is usually a small share of revenue but real cash margin. Many independents also run lines a chain store does not: long-term care supply contracts, compounding, immunizations, durable medical equipment. Each earns and transfers differently, so a lender asks for the business broken into its lines before it asks what the whole is worth. The SBA lending data for pharmacies and drug retailers shows how active SBA lenders are in the trade and how its acquisition loans compare with the program as a whole.
| Revenue line | What the lender asks | Why it matters after a sale |
|---|---|---|
| Retail prescriptions (commercial, Part D, Medicaid) | Script count and gross profit per script by payer, by month, for two to three years | Reimbursement is set by contracts the buyer inherits or must re-sign; a falling margin per script matters more than a steady count |
| Long-term care facility contracts | Which facilities, how many beds, contract terms and change-of-control clauses | A single facility contract can be a large, concentrated block of revenue that can be moved to another pharmacy |
| Compounding | Payer acceptance, regulatory inspections, who does the compounding | Often depends on one pharmacist's skill and on payers continuing to cover compounded claims |
| Front-end retail | Sales and margin, shrink, inventory age | Steady cash margin; valued, but rarely what the price is paid for |
What transfers with the store, and what has to be issued again
The single largest execution risk in a pharmacy deal is a gap between closing and the buyer's ability to dispense and bill. A pharmacy that cannot adjudicate claims has almost no revenue that week, and it still owes the wholesaler. Lenders therefore want the regulatory sequence mapped before they commit, and they write the key approvals into their closing conditions. Whether the deal is an asset purchase or a purchase of the selling company's stock changes what has to be redone; asset vs stock purchase covers the general trade-off, but for a pharmacy the regulatory side often decides it.
| Item | What usually happens on a sale | What the lender wants to see |
|---|---|---|
| State pharmacy permit | Issued to an owner at a location; most boards of pharmacy treat a change of ownership as needing a new permit or prior approval | The board's requirements and timing, and the permit as a condition of funding |
| DEA registration | Cannot be assigned without DEA's written consent, so the buyer usually registers in its own name; controlled-substance inventory moves under DEA transfer procedures with a documented count | The buyer's registration in hand before controlled substances change hands |
| Payer and PBM network contracts | Contracted with the owning entity; in an asset purchase the buyer usually credentials anew, and even a stock purchase can trigger notice or change-of-ownership clauses | A credentialing plan that avoids a billing gap, and which contracts are being assumed |
| Medicare and Medicaid enrollment | Change-of-ownership filings are required; supplier enrollment for equipment is separate | Filings made on time, with the buyer's enrollment effective at closing |
| Prescription files and patient records | Transfer with the sale, subject to privacy rules | Evidence that patients will stay, such as the plan for notifying them and keeping staff |
| Lease | Assigned with landlord consent | A term that runs at least as long as the loan; see lease assignment |
A pharmacy that cannot bill on the day after closing has almost no revenue that week. Lenders want the permit, DEA and credentialing sequence in writing before they fund.
The pharmacist question
Every pharmacy needs a licensed pharmacist-in-charge, and lenders ask who that will be before almost anything else. A buyer who is a pharmacist and will run the counter is the simplest case: management experience is direct, and the owner resume that supports SBA Form 1919 does most of the work. A few states also restrict who may own a pharmacy, which a buyer should check first.
A buyer who is not a pharmacist, an investor, a searcher or an operator from outside healthcare, can still finance a pharmacy, but the credit then rests on a hired pharmacist-in-charge. Lenders look at that person's tenure in the store, their employment terms, and whether a second pharmacist could step in. See industry experience requirements for how lenders weigh a buyer from outside the trade.
The retiring owner-pharmacist is the complication many buyers miss. Sellers often want to keep working a few shifts a week, and buyers often want them to. In a complete change of ownership financed by SBA, the seller may not stay on as an owner, officer or employee. The seller may consult for up to 12 months, and from 1 October 2026, under SOP 50 10 8.1, for up to 24 months. A plan in which the seller keeps working as a staff pharmacist for years does not fit that rule; it needs a partial change of ownership, a conventional loan, or a different staffing plan.
Inventory, receivables and the cash the buyer will need
Pharmacy prices are commonly quoted as a price for the business plus inventory at cost, counted at closing, often by an outside inventory service. The inventory is a large and real asset, but lenders value it more carefully than the seller does. Expired and short-dated stock, slow-moving items and anything that cannot be returned to the wholesaler are worth less than cost. SBA 7(a) can finance inventory as part of the purchase. On a conventional structure, asset-based lenders typically advance up to 85% of net orderly liquidation value on inventory, or roughly half of cost; see inventory advance rates.
Working capital is where pharmacy acquisitions most often come up short. The pharmacy pays its wholesaler on short terms, while payers remit on their own cycles, so receivables from PBMs are always outstanding. A buyer who spends every available dollar on the price and the inventory can find the business short of cash within weeks of closing. Lenders want to see working capital funded at closing, either in the loan or from the buyer; working capital at close explains how it is sized.
Payers can also recover money after the fact: audit recoupments on claims the seller submitted, and fees assessed months after a prescription was filled. The purchase agreement should say who bears adjustments that relate to claims before closing. An escrow or holdback is the usual answer, and lenders read that clause.
How the deal is usually put together
For a single independent store bought by an owner-operator, SBA 7(a) is the common route. It finances the goodwill that makes up most of a pharmacy's price, along with inventory and working capital, over up to 10 years. Where the building is included, the real estate share can run up to 25 years. SBA guarantees 75% of loans above $150,000, which is why lenders will finance a price that is mostly goodwill with little hard collateral behind it.
| Piece of the deal | SBA 7(a) | Conventional |
|---|---|---|
| Senior loan | Up to $5 million; goodwill, inventory and working capital over up to 10 years | Sized to earnings, commonly 2x to 3.5x EBITDA, often with a separate inventory and receivables line |
| Buyer equity | At least 10% of total project costs | Usually more, set by the lender and the deal |
| Seller note | Counts for up to half of the injection only on full standby for the life of the loan; otherwise it is debt in the coverage test | Subordinated to the bank, with payments allowed if covenants are met |
| Earnout tied to script retention | Not allowed in a change of ownership SBA finances | Possible, but lenders limit what can be paid out |
| Seller staying on | Consulting only, up to 12 months (24 months from 1 October 2026) | Negotiable |
| Valuation | Independent business valuation required where the amount financed, less appraised real estate and equipment, exceeds $250,000 | Lender's own valuation view |
Two changes take effect on 1 October 2026 under SOP 50 10 8.1. Financial due diligence becomes required on every change of ownership, and a quality of earnings report on acquisitions of $3 million or more, excluding real estate. And a change of ownership must show debt service coverage of 1.25x on historical results, not on projections. For a pharmacy whose margin per script has been drifting down, the historical test is the one that binds. More on sizing in SBA 7(a) acquisition loans and on the note in seller notes and SBA's full-standby rule.
The risks lenders price in a pharmacy
- Reimbursement pressure. Lenders look at gross profit per prescription over several years, not one. A steady script count with a shrinking margin is a declining business.
- Payer and customer concentration. One PBM carrying a large share of claims, or one long-term care contract carrying a large share of revenue, is priced as concentration; see customer concentration.
- Audit exposure. A history of recoupments or open audits points to billing practices. In a stock purchase the liability comes with the company; in either structure the staff and habits that produced it usually stay.
- Controlled-substance compliance. Board discipline or DEA findings against the store are read as a risk to the permit and to the buyer's own registration.
- Staff continuity. Patients follow pharmacists and technicians they know. Lenders ask who is staying and on what terms.
What goes in the file
The standard acquisition documents come first, as set out in what lenders need to finance an acquisition: the target's business tax returns for two to three years, P&L and balance sheet, a year-to-date P&L through last month-end, its latest full year of figures (never an older year), the debt schedule, the letter of intent, and each 20% owner's personal tax returns and personal financial statement. For a pharmacy, these shorten underwriting:
- Monthly prescription counts and gross profit by payer for the last two to three years, from the pharmacy system.
- Payer and PBM audit history, with any recoupments and open audits.
- A list of permits, registrations and enrollments, with who holds each and the plan to reissue or transfer it.
- Long-term care and other supply contracts, with their change-of-control terms.
- The most recent inventory count and wholesaler purchase history.
- Board of pharmacy inspection reports.
- The pharmacist-in-charge plan and a staff roster with tenure.
Once those documents are in, Transparent builds the lender package, the financing model, lender presentation, blind teaser and underwriting memo, in a day, and takes it to the lenders in its book that finance pharmacies. What those documents contain is on the package.
Common questions
- Can a non-pharmacist buy a pharmacy with an SBA loan?
- Often, yes, where state law allows it. The credit then depends on the pharmacist-in-charge the buyer will employ: their tenure, their terms and whether there is a backup. Lenders weigh a strong hired pharmacist against the buyer's own management experience in the business.
- Will SBA finance the inventory?
- Yes. Inventory can be part of the project SBA 7(a) finances, along with goodwill and working capital. Lenders value it on what it would really fetch, so expired, short-dated and non-returnable stock counts for less than cost.
- Can the selling pharmacist keep working a few shifts after closing?
- Not as an employee in a complete change of ownership financed by SBA. The seller may consult for up to 12 months, or up to 24 months from 1 October 2026. If the business needs the seller behind the counter longer, the deal needs a different structure.
- What if the pharmacy's reimbursement has been falling?
- Lenders size the loan on the recent trend, not the best year. From 1 October 2026 an SBA change of ownership must show 1.25x debt service coverage on historical results, so a pharmacy with a shrinking margin per script supports a smaller loan, and the gap has to come from more equity or a seller note on full standby.
- Is it better to buy the pharmacy's stock or its assets?
- It depends on the contracts and the state. A stock purchase can keep some payer contracts and enrollments in place but brings the seller's liabilities, including audit exposure. An asset purchase leaves those behind but usually means credentialing anew. Lenders finance either, provided the gap between closing and billing is planned.